Insamo emerges from stealth with $12 million in seed capital to develop orally administered, membrane-permeable cyclic peptides across disease areas. Co-founder and CEO Timothy Craven says the company’s name is a portmanteau of “internally satisfied molecules.”
UC Berkeley spins out Insamo, a start-up developing oral cyclic peptides to replace injected medicines. The company raises $12 million, including investment from Merck MRL Ventures Fund.
Berkeley-based biotech Insamo launches with a $12 million seed round that includes venBio and Playground Global. The startup aims to develop macrocyclic peptide drugs as oral alternatives to injected biologics, pursuing the broader goal of turning blockbuster biologic medicines such as Dupixent into pills.
Insamo launches with seed financing from Playground Global, venBio, and MRL Ventures Fund to develop membrane-permeable macrocyclic peptides. The announcement names the financing participants and the company’s development focus.
